Analysts expect Repligen Co. (NASDAQ:RGEN) to post $0.12 earnings per share for the current fiscal quarter, Zacks reports. Five analysts have issued estimates for Repligen’s earnings, with the highest EPS estimate coming in at $0.13 and the lowest estimate coming in at $0.11. Repligen posted earnings per share of $0.08 during the same quarter last year, which indicates a positive year-over-year growth rate of 50%. The business is scheduled to announce its next earnings results on Wednesday, February 28th.
On average, analysts expect that Repligen will report full-year earnings of $0.61 per share for the current financial year, with EPS estimates ranging from $0.57 to $0.63. For the next financial year, analysts forecast that the company will post earnings of $0.71 per share, with EPS estimates ranging from $0.68 to $0.75. Zacks Investment Research’s EPS calculations are a mean average based on a survey of research analysts that that provide coverage for Repligen.
Repligen (NASDAQ:RGEN) last posted its quarterly earnings results on Thursday, November 9th. The biotechnology company reported $0.15 EPS for the quarter, beating the Zacks’ consensus estimate of $0.11 by $0.04. The business had revenue of $36.58 million for the quarter, compared to analysts’ expectations of $35.69 million. Repligen had a return on equity of 7.57% and a net margin of 16.93%. The business’s quarterly revenue was up 48.2% on a year-over-year basis. During the same period last year, the firm earned $0.08 earnings per share.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in RGEN. JPMorgan Chase & Co. grew its holdings in Repligen by 31.9% in the first quarter. JPMorgan Chase & Co. now owns 3,755 shares of the biotechnology company’s stock worth $133,000 after purchasing an additional 908 shares during the last quarter. Teachers Advisors LLC grew its holdings in shares of Repligen by 2.4% during the first quarter. Teachers Advisors LLC now owns 58,081 shares of the biotechnology company’s stock valued at $2,044,000 after buying an additional 1,386 shares during the last quarter. Vanguard Group Inc. grew its holdings in shares of Repligen by 7.0% during the first quarter. Vanguard Group Inc. now owns 1,809,202 shares of the biotechnology company’s stock valued at $63,683,000 after buying an additional 118,585 shares during the last quarter. Bank of America Corp DE grew its holdings in shares of Repligen by 55.2% during the first quarter. Bank of America Corp DE now owns 93,003 shares of the biotechnology company’s stock valued at $3,274,000 after buying an additional 33,084 shares during the last quarter. Finally, Public Employees Retirement System of Ohio grew its holdings in shares of Repligen by 16.1% during the first quarter. Public Employees Retirement System of Ohio now owns 10,127 shares of the biotechnology company’s stock valued at $356,000 after buying an additional 1,401 shares during the last quarter. 83.31% of the stock is currently owned by institutional investors and hedge funds.
Repligen (RGEN) traded down $0.16 during trading hours on Monday, reaching $34.58. The company’s stock had a trading volume of 400,984 shares, compared to its average volume of 325,183. The company has a market capitalization of $1,529.14, a PE ratio of 60.52, a PEG ratio of 2.29 and a beta of 1.04. Repligen has a twelve month low of $28.48 and a twelve month high of $46.81.
COPYRIGHT VIOLATION WARNING: “Analysts Anticipate Repligen Co. (RGEN) Will Post Earnings of $0.12 Per Share” was reported by Community Financial News and is the sole property of of Community Financial News. If you are viewing this story on another site, it was copied illegally and reposted in violation of U.S. and international trademark & copyright laws. The legal version of this story can be read at https://www.com-unik.info/2017/12/07/analysts-anticipate-repligen-co-rgen-will-post-earnings-of-0-12-per-share.html.
Repligen Corporation is a bioprocessing company. The Company is focused on the development, manufacture and commercialization of products used to improve the interconnected phases of the biological drug manufacturing process. The Company’s portfolio includes protein products, chromatography products, and filtration products.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
What are top analysts saying about Repligen Co.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Repligen Co. and related companies.